DexCom, Inc. vs Pfizer, Inc. — Stock Comparison
DexCom, Inc. (DXCM) and Pfizer, Inc. (PFE) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
DexCom, Inc. clearly outscores Pfizer, Inc. on Q·Score (8 vs 6.1 out of 10), led by Growth (8.9 vs 5.1) and Quality (9.3 vs 5.7). Pfizer, Inc. scores higher on Valuation, reflecting stronger P/E and price-target positioning. Analyst consensus targets imply greater upside for PFE (+14.9%) than for DXCM (+3.2%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
High-quality business with 38% return on equity and 20% profit margins.
Forward P/E of 8.8× is low relative to sector peers.
⚠ earnings contracting 10% year-over-year.
Analyst Consensus
Fundamentals
Frequently Asked Questions
DXCM vs PFE: which stock scores better overall?
Based on Q·Score, DexCom, Inc. (DXCM) scores 8/10 versus Pfizer, Inc. (PFE) at 6.1/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: DXCM or PFE?
DexCom, Inc. (DXCM) scores higher on Growth (8.9/10 vs 5.1/10). DexCom, Inc. reports revenue growth (13.1% YoY) while Pfizer, Inc. reports (5.4% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is DXCM or PFE more attractively valued?
Pfizer, Inc. (PFE) scores higher on Valuation (7.2/10 vs 5.8/10). DXCM trades at 26.8× P/E versus PFE at 8.8×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about DXCM vs PFE?
There are 25 analysts covering DXCM with a consensus price target of $86.16, and 26 analysts covering PFE with a consensus target of $28.75. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: DXCM or PFE?
DexCom, Inc. (DXCM) scores higher on Quality (9.3/10 vs 5.7/10). Net profit margin: DXCM at 20.1%, PFE at 11.8%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: DXCM or PFE?
DexCom, Inc. (DXCM) scores higher on Financial Health (7.6/10 vs 7/10). Market beta: DXCM at 1.45, PFE at 0.31. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of DXCM and PFE?
DexCom, Inc. (DXCM) has a market capitalisation of $31.5B, while Pfizer, Inc. (PFE) has a market cap of —. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do DXCM or PFE pay dividends?
DXCM does not currently pay a dividend, while PFE pays a dividend yield of 6.88%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →